Stock Ratings from Analyst Ratings Network

Open Main Menu Open Sidebar

BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

Consensus Ratings for BioCryst Pharmaceuticals (NASDAQ:BCRX) (?)
Ratings Breakdown: 2 Hold Rating(s), 9 Buy Rating(s)
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $18.33 (54.97% upside)

Current Analysts' Coverage Summary for BioCryst Pharmaceuticals (NASDAQ:BCRX)
Show:
DateFirmActionRatingPrice TargetDetailsShare
8/8/2014JPMorgan Chase & Co.Initiated CoverageOverweight$20.00ViewTweet This Rating  Share This Rating on StockTwits
6/23/2014Wells Fargo & Co.UpgradeMarket Perform -> Outperform$19.00 -> $17.00ViewTweet This Rating  Share This Rating on StockTwits
5/30/2014HC WainwrightBoost Price TargetBuy$21.00 -> $24.00ViewTweet This Rating  Share This Rating on StockTwits
5/28/2014Roth CapitalBoost Price Target$18.00 -> $20.00ViewTweet This Rating  Share This Rating on StockTwits
5/28/2014Bank of AmericaReiterated RatingPositiveViewTweet This Rating  Share This Rating on StockTwits
4/14/2014Brinson PatrickInitiated CoverageOutperform$15.00ViewTweet This Rating  Share This Rating on StockTwits
3/4/2014MLV & Co Boost Price TargetBuy$9.00 -> $15.00ViewTweet This Rating  Share This Rating on StockTwits
2/28/2014OppenheimerInitiated CoverageMarket PerformViewTweet This Rating  Share This Rating on StockTwits
2/20/2014Piper JaffrayInitiated CoverageOverweight$17.00ViewTweet This Rating  Share This Rating on StockTwits
2/20/2014MizuhoInitiated CoverageBuy$23.00ViewTweet This Rating  Share This Rating on StockTwits
2/18/2014Needham & Company LLCInitiated CoverageBuy$14.00ViewTweet This Rating  Share This Rating on StockTwits
1/13/2014JMP SecuritiesReiterated RatingMarket PerformViewTweet This Rating  Share This Rating on StockTwits
7/23/2013Noble FinancialUpgradeHold -> BuyViewTweet This Rating  Share This Rating on StockTwits
(Data available from 10/25/2012 forward)
Discuss BioCryst Pharmaceuticals